UNSPSC 51323103: Bervastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C28H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 057SF9C1UZ, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)spiro(2h-1-benzopyran-2,1-cyclopentan)-3-yl)-3,5-dihydroxy-, ethyl ester, (3r,5s,6e)-rel- but generally known as bervastatin, which bears US NIH Compound Identifier 6436003. European Medicines Agency schedules Bervastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05785MIG.

UNSPSC 51323103 Bervastatin, a Commodity code, represents pharmaceutical products purchased by state and local governments for emergency medical services, health benefit programs, and health care facilities. State and local buyers solicit these medications through a mix of IFB notices for immediate-need emergency supplies and RFI/RFP mechanisms for longer-term pharmacy benefit contracts and cooperative purchasing agreements. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and multistate cooperative purchasing alliances such as MMCAP all use variants of this code when sourcing pharmaceuticals, though the actual medications vary widely by use case—from advanced life support drugs like epinephrine and diltiazem for emergency response to generic multi-source drugs and OTC products for health plan members across participating jurisdictions.

Recent activity spans Florida, Texas, and the Upper Midwest through Minnesota's cooperative purchasing vehicle. The most concrete near-term opportunity is the City of Tampa's Purchasing Department IFB No. 26P00188 for Advanced Life Support Medications, posted April 24, 2026, with a due date of April 8, 2026 (note: due date predates posting), seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg for Tampa Fire Rescue, with an estimated contract value of $40,000 and a SLBE sheltered market designation offering a 5 percent bid discount not to exceed $10,000. The Texas HHS Commission issued RFI No. HHS0017013 on April 3, 2026, to assess vendor capabilities for direct-to-manufacturer prescription programs, a preliminary stage in pharmacy benefit design with no budget disclosed. The Minnesota Department of Administration's MMCAP RFP for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, targets multi-state distribution through authorized wholesalers with contract effectiveness July 1, 2026, and awards weighted 75 percent on price competitiveness. All solicitations require FDA compliance, expiration-date certifications, and in the cooperative case, cGMP and DSCSA certifications with insurance thresholds of $5 million general liability.